vs
IRIDEX CORP（IRIX）与LivaNova PLC（LIVN）财务数据对比。点击上方公司名可切换其他公司
LivaNova PLC的季度营收约是IRIDEX CORP的24.5倍（$360.9M vs $14.7M），LivaNova PLC同比增速更快（12.1% vs -69.7%），过去两年IRIDEX CORP的营收复合增速更高（11.9% vs 10.6%）
IRIDEX Corporation是一家全球性医疗科技企业，主要研发、生产和销售面向眼科及医疗美容领域的激光类医疗设备，产品供应至北美、欧洲、亚太等地区的医疗机构与诊所，为眼部疾病治疗和医美项目提供微创解决方案。
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
IRIX vs LIVN — 直观对比
营收规模更大
LIVN
是对方的24.5倍
$14.7M
营收增速更快
LIVN
高出81.9%
-69.7%
两年增速更快
IRIX
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.7M | $360.9M |
| 净利润 | — | $30.9M |
| 毛利率 | 37.2% | 65.2% |
| 营业利润率 | — | 11.8% |
| 净利率 | — | 8.6% |
| 营收同比 | -69.7% | 12.1% |
| 净利润同比 | — | -44.7% |
| 每股收益（稀释后） | — | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IRIXLIVN
| Q4 25 | $14.7M | $360.9M | ||
| Q3 25 | $12.5M | $357.8M | ||
| Q2 25 | $13.6M | $352.5M | ||
| Q1 25 | $11.9M | $316.9M | ||
| Q4 24 | $12.7M | $321.8M | ||
| Q3 24 | $11.6M | $318.1M | ||
| Q2 24 | $12.6M | $318.6M | ||
| Q1 24 | $11.8M | $294.9M |
净利润IRIXLIVN
| Q4 25 | — | $30.9M | ||
| Q3 25 | $-1.6M | $26.8M | ||
| Q2 25 | $-994.0K | $27.2M | ||
| Q1 25 | $-1.7M | $-327.3M | ||
| Q4 24 | $-834.0K | $55.9M | ||
| Q3 24 | $-1.9M | $33.0M | ||
| Q2 24 | $-2.7M | $16.3M | ||
| Q1 24 | $-3.5M | $-41.9M |
毛利率IRIXLIVN
| Q4 25 | 37.2% | 65.2% | ||
| Q3 25 | 32.1% | 68.4% | ||
| Q2 25 | 34.5% | 67.8% | ||
| Q1 25 | 42.5% | 69.7% | ||
| Q4 24 | 44.0% | 68.2% | ||
| Q3 24 | 37.3% | 70.8% | ||
| Q2 24 | 40.7% | 68.7% | ||
| Q1 24 | 37.9% | 70.3% |
营业利润率IRIXLIVN
| Q4 25 | — | 11.8% | ||
| Q3 25 | -11.3% | 15.1% | ||
| Q2 25 | -6.9% | 15.4% | ||
| Q1 25 | -1.7% | 15.3% | ||
| Q4 24 | -3.9% | 11.5% | ||
| Q3 24 | -16.1% | 11.2% | ||
| Q2 24 | -20.9% | 12.6% | ||
| Q1 24 | -28.0% | 5.5% |
净利率IRIXLIVN
| Q4 25 | — | 8.6% | ||
| Q3 25 | -12.6% | 7.5% | ||
| Q2 25 | -7.3% | 7.7% | ||
| Q1 25 | -14.2% | -103.3% | ||
| Q4 24 | -6.6% | 17.4% | ||
| Q3 24 | -16.7% | 10.4% | ||
| Q2 24 | -21.2% | 5.1% | ||
| Q1 24 | -29.5% | -14.2% |
每股收益（稀释后）IRIXLIVN
| Q4 25 | — | $0.57 | ||
| Q3 25 | $-0.09 | $0.49 | ||
| Q2 25 | $-0.06 | $0.50 | ||
| Q1 25 | $-0.10 | $-6.01 | ||
| Q4 24 | $-0.05 | $1.04 | ||
| Q3 24 | $-0.12 | $0.60 | ||
| Q2 24 | $-0.16 | $0.30 | ||
| Q1 24 | $-0.21 | $-0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.0M | $635.6M |
| 总债务越低越好 | — | $376.1M |
| 股东权益账面价值 | — | $1.2B |
| 总资产 | $29.2M | $2.6B |
| 负债/权益比越低杠杆越低 | — | 0.31× |
8季度趋势，按日历期对齐
现金及短期投资IRIXLIVN
| Q4 25 | $6.0M | $635.6M | ||
| Q3 25 | $5.6M | $646.1M | ||
| Q2 25 | $6.8M | $593.6M | ||
| Q1 25 | $7.2M | $738.4M | ||
| Q4 24 | $2.4M | $428.9M | ||
| Q3 24 | $3.9M | $346.4M | ||
| Q2 24 | $4.1M | $329.2M | ||
| Q1 24 | $5.4M | $309.2M |
总债务IRIXLIVN
| Q4 25 | — | $376.1M | ||
| Q3 25 | — | $434.5M | ||
| Q2 25 | — | $430.6M | ||
| Q1 25 | — | $628.2M | ||
| Q4 24 | $1.0M | $627.0M | ||
| Q3 24 | $1.4M | $625.5M | ||
| Q2 24 | — | $624.5M | ||
| Q1 24 | — | $623.8M |
股东权益IRIXLIVN
| Q4 25 | — | $1.2B | ||
| Q3 25 | $4.7M | $1.2B | ||
| Q2 25 | $6.1M | $1.1B | ||
| Q1 25 | $852.0K | $1.0B | ||
| Q4 24 | $2.1M | $1.3B | ||
| Q3 24 | $2.6M | $1.3B | ||
| Q2 24 | $4.2M | $1.2B | ||
| Q1 24 | $6.5M | $1.2B |
总资产IRIXLIVN
| Q4 25 | $29.2M | $2.6B | ||
| Q3 25 | $28.4M | $2.6B | ||
| Q2 25 | $31.6M | $2.5B | ||
| Q1 25 | $34.2M | $2.6B | ||
| Q4 24 | $29.1M | $2.5B | ||
| Q3 24 | $30.2M | $2.5B | ||
| Q2 24 | $31.2M | $2.5B | ||
| Q1 24 | $34.1M | $2.5B |
负债/权益比IRIXLIVN
| Q4 25 | — | 0.31× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.61× | ||
| Q4 24 | 0.48× | 0.47× | ||
| Q3 24 | 0.53× | 0.48× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $82.4M |
| 自由现金流经营现金流 - 资本支出 | — | $50.2M |
| 自由现金流率自由现金流/营收 | — | 13.9% |
| 资本支出强度资本支出/营收 | — | 8.9% |
| 现金转化率经营现金流/净利润 | — | 2.67× |
| 过去12个月自由现金流最近4个季度 | — | $173.3M |
8季度趋势，按日历期对齐
经营现金流IRIXLIVN
| Q4 25 | — | $82.4M | ||
| Q3 25 | $-1.2M | $85.1M | ||
| Q2 25 | $-397.0K | $62.9M | ||
| Q1 25 | $-1.1M | $24.0M | ||
| Q4 24 | $-1.2M | $78.7M | ||
| Q3 24 | $-3.1M | $51.0M | ||
| Q2 24 | $-1.3M | $43.4M | ||
| Q1 24 | $-1.6M | $10.0M |
自由现金流IRIXLIVN
| Q4 25 | — | $50.2M | ||
| Q3 25 | $-1.2M | $62.2M | ||
| Q2 25 | $-410.0K | $47.8M | ||
| Q1 25 | $-1.2M | $13.2M | ||
| Q4 24 | $-1.2M | $68.3M | ||
| Q3 24 | $-3.1M | $32.8M | ||
| Q2 24 | — | $31.2M | ||
| Q1 24 | $-1.7M | $3.6M |
自由现金流率IRIXLIVN
| Q4 25 | — | 13.9% | ||
| Q3 25 | -9.4% | 17.4% | ||
| Q2 25 | -3.0% | 13.6% | ||
| Q1 25 | -9.8% | 4.2% | ||
| Q4 24 | -9.8% | 21.2% | ||
| Q3 24 | -26.5% | 10.3% | ||
| Q2 24 | — | 9.8% | ||
| Q1 24 | -14.0% | 1.2% |
资本支出强度IRIXLIVN
| Q4 25 | — | 8.9% | ||
| Q3 25 | 0.1% | 6.4% | ||
| Q2 25 | 0.1% | 4.3% | ||
| Q1 25 | 0.1% | 3.4% | ||
| Q4 24 | 0.1% | 3.2% | ||
| Q3 24 | 0.0% | 5.7% | ||
| Q2 24 | 0.0% | 3.8% | ||
| Q1 24 | 0.0% | 2.2% |
现金转化率IRIXLIVN
| Q4 25 | — | 2.67× | ||
| Q3 25 | — | 3.18× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.41× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 2.65× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IRIX
暂无分部数据
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
